Literature DB >> 28830902

Zoster vaccine-associated primary varicella infection in an immunocompetent host.

Kaoru Harada1, Henry Heaton2, Jason Chen3, Marietta Vazquez4, Jaimie Meyer5.   

Abstract

A 64-year-old immunocompetent man developed a widespread pruritic and vesicular rash 2 weeks after receiving the zoster vaccine (Zostavax). He had fever, bandaemia with normal total white blood cell count and mild transaminitis. PCR testing of serum and skin was positive for varicella zoster virus (VZV), while serum VZV IgG was negative. The analysis of single nucleotide polymorphism by PCR and sequencing from the skin swab was consistent with the vaccine strain. The patient received 1 week of intravenous acyclovir and was discharged after all lesions had crusted. He continues to do well on follow-up with no significant complications. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  immunological products and vaccines; safety; skin; unwanted effects / adverse reactions; vaccination/immunisation

Mesh:

Substances:

Year:  2017        PMID: 28830902      PMCID: PMC5624100          DOI: 10.1136/bcr-2017-221166

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster.

Authors:  Mark L Quinlivan; Nancy J Jensen; Kay W Radford; D Scott Schmid
Journal:  J Clin Microbiol       Date:  2012-02-29       Impact factor: 5.948

2.  Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial.

Authors:  Michael S Simberkoff; Robert D Arbeit; Gary R Johnson; Michael N Oxman; Kathy D Boardman; Heather M Williams; Myron J Levin; Kenneth E Schmader; Lawrence D Gelb; Susan Keay; Kathleen Neuzil; Richard N Greenberg; Marie R Griffin; Larry E Davis; Vicki A Morrison; Paula W Annunziato
Journal:  Ann Intern Med       Date:  2010-05-04       Impact factor: 25.391

3.  Live vaccine used to prevent the spread of varicella in children in hospital.

Authors:  M Takahashi; T Otsuka; Y Okuno; Y Asano; T Yazaki
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

4.  A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Authors:  M N Oxman; M J Levin; G R Johnson; K E Schmader; S E Straus; L D Gelb; R D Arbeit; M S Simberkoff; A A Gershon; L E Davis; A Weinberg; K D Boardman; H M Williams; J Hongyuan Zhang; P N Peduzzi; C E Beisel; V A Morrison; J C Guatelli; P A Brooks; C A Kauffman; C T Pachucki; K M Neuzil; R F Betts; P F Wright; M R Griffin; P Brunell; N E Soto; A R Marques; S K Keay; R P Goodman; D J Cotton; J W Gnann; J Loutit; M Holodniy; W A Keitel; G E Crawford; S-S Yeh; Z Lobo; J F Toney; R N Greenberg; P M Keller; R Harbecke; A R Hayward; M R Irwin; T C Kyriakides; C Y Chan; I S F Chan; W W B Wang; P W Annunziato; J L Silber
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

5.  Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study.

Authors:  H F Tseng; A Liu; L Sy; S M Marcy; B Fireman; E Weintraub; J Baggs; S Weinmann; R Baxter; J Nordin; M F Daley; L Jackson; S J Jacobsen
Journal:  J Intern Med       Date:  2011-11-22       Impact factor: 8.989

6.  Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates.

Authors:  P LaRussa; O Lungu; I Hardy; A Gershon; S P Steinberg; S Silverstein
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

Review 7.  Immunization of immunocompromised persons.

Authors:  David J Weber; William A Rutala
Journal:  Immunol Allergy Clin North Am       Date:  2003-11       Impact factor: 3.479

8.  Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient.

Authors:  E Costa; J Buxton; J Brown; K E Templeton; J Breuer; I Johannessen
Journal:  BMJ Case Rep       Date:  2016-05-04

9.  Herpes zoster caused by vaccine-strain varicella zoster virus in an immunocompetent recipient of zoster vaccine.

Authors:  Hung Fu Tseng; D Scott Schmid; Rafael Harpaz; Philip LaRussa; Nancy J Jensen; Pierre Rivailler; Kay Radford; Jennifer Folster; Steven J Jacobsen
Journal:  Clin Infect Dis       Date:  2014-01-26       Impact factor: 9.079

10.  Update on recommendations for use of herpes zoster vaccine.

Authors:  Craig M Hales; Rafael Harpaz; Ismael Ortega-Sanchez; Stephanie R Bialek
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-08-22       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.